Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05230173 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05230173 · ClinicalTrials.gov record · last posted 2026-08-07

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

Study acronym: QUOTIENT
StatusRecruiting
PhaseNot applicable
Started2022-10-05
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis \[UC\]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.

Protocol amendment history 4 changes detected by DataLookout

2026-08-08
Enrollment reduced: 250 → 216 participants
2026-08-08
Sponsor changed: University of California, San Diego → Mayo Clinic
WasUniversity of California, San Diego
NowMayo Clinic
2026-08-08
Primary completion pushed: 2028-03-01 → 2028-08-01
2026-08-08
Completion pushed: 2028-06-01 → 2029-02-01
Trial Details
NCT Number NCT05230173
Lead Sponsor Mayo Clinic
Collaborators: Baylor College of Medicine, Crohn's and Colitis Foundation, Western University, Patient-Centered Outcomes Research Institute
Conditions Ulcerative Colitis, Crohn Disease
Enrollment 216 participants
Start Date 2022-10-05
Primary Completion 2028-08-01 (estimated)
Study Completion 2029-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-07